Injection of recombinant activated factor VII can induce transient increase in circulating procoagulant microparticles

Thrombosis and Haemostasis

Volumn 91, Issue 5, 2004, Pages 873-878

  Proulle, Valérie ^a   Hugel, Bénédicte ^a,b   Guillet, Benoit ^a   Trichet, Catherine ^a   Rafowicz, Anne ^a   Lambert, Thierry ^a   Freyssinet, Jean Marie ^a,b   Dreyfus, Marie ^a  

^a BICÊTRE HOSPITAL   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Haemophilia therapy; Microparticle; Platelet activation

Indexed keywords

BLOOD CLOTTING FACTOR 7A INHIBITOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; DESMOPRESSIN; HEMOSTATIC AGENT; PROCOAGULANT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; THROMBIN;

ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MEASUREMENT; PARTICULATE MATTER; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION;

EID: 2442429227     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-05-0301     Document Type: Article

References (15)

1. Butenas S, Brummel KE, Branda RF, et al. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood 2002; 99: 923-30.
2. Hoffman M, Monroe DM, 3rd, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998; 9 Suppl 1: S61-65.
3. Hoffman M, Monroe DM, 3rd. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol 2001; 38: 6-9.
4. Butenas S, Brummel KE, Bouchard BA, et al. How factor VIIa works in hemophilia. J Thromb Haemost 2003; 1: 1158-60.
5. Hugel B, Socie G, Vu T, et al. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood 1999; 93: 3451-6.
6. Lee DH, Warkentin TE, Denomme GA, et al. A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry. Br J Haematol 1996; 95: 724-31.
7. Mallat Z, Benamer H, Hugel B, et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841-3.
8. Kasper CK, Aledort L, Aronson D, et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612.
9. Aupeix K, Hugel B, Martin T, et al. The significance of shed membrane particles during programmed cell death in vitro, and in vivo, in HIV-1 infection. J Clin Invest 1997; 99: 1546-54.
10. Key NS, Slungaard A, Dandelet L, et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998; 91: 4216-23.
11. Sumner WT, Monroe DM, Hoffman M. Variability in platelet procoagulant activity in healthy volunteers. Thromb Res 1996; 81: 533-43.
12. Butenas S, van't Veer C, Mann KG. "Normal" thrombin generation, Blood 1999; 94: 2169-78.
13. Blann AD, Lanza F, Galajda P, et al. Increased platelet glycoprotein V levels in patients with coronary and peripheral atherosclerosis. Thromb Haemost 2001; 86: 777-83.
14. Ravanat C, Freund M, Mangin P, et al. GPV is a marker of in vivo platelet activation - study in a rat thrombosis model. Thromb Haemost 2000; 83: 327-33.
15. Hrachovinova I, Cambien B, Hafezi-Moghadam A, et al. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat Med 2003; 9: 1020-5.